These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25316185)

  • 21. Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi P
    Eur Urol Oncol; 2019 Sep; 2(5):576-583. PubMed ID: 31411974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).
    Pierconti F; Straccia P; Emilio S; Bassi PF; De Pascalis I; Marques RC; Volavsek M; Larocca LM; Lopez-Beltran A
    Pathol Res Pract; 2017 Sep; 213(9):1078-1081. PubMed ID: 28843746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis.
    Zhou W; Liu J; Mao D; Hu C; Gao D
    PLoS One; 2022; 17(10):e0276453. PubMed ID: 36269742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
    Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
    Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.
    Onishi T; Sekito S; Shibahara T; Uchida K; Sasaki T
    Scand J Urol; 2018; 52(5-6):385-388. PubMed ID: 30628540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer.
    Onishi T; Sugino Y; Shibahara T; Masui S; Yabana T; Sasaki T
    BJU Int; 2017 Feb; 119(2):276-282. PubMed ID: 27444991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
    Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
    [No Abstract]   [Full Text] [Related]  

  • 28. Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.
    Ersoy H; Yaytokgil M; Karakoyunlu AN; Topaloglu H; Sagnak L; Ozok HU
    Drug Des Devel Ther; 2013; 7():1-6. PubMed ID: 23300343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
    Rouprêt M; Neuzillet Y; Larré S; Pignot G; Coloby P; Rébillard X; Mongiat-Artus P; Chartier-Kastler E; Soulié M; Pfister C;
    Prog Urol; 2012 Nov; 22(15):920-31. PubMed ID: 23102014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer.
    Batura D; Hashemzehi T; Colemeadow J
    Int Urol Nephrol; 2018 Jun; 50(6):1053-1059. PubMed ID: 29611146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer.
    Slater SE; Patel P; Viney R; Foster M; Porfiri E; James ND; Montgomery B; Bryan RT
    Ann R Coll Surg Engl; 2014 Sep; 96(6):415-9. PubMed ID: 25198970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?
    Kiss B; Schneider S; Thalmann GN; Roth B
    Int J Urol; 2015 Feb; 22(2):158-62. PubMed ID: 25339291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
    Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG
    Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer.
    Maffezzini M; Campodonico F; Manuputty EE; Puntoni M; Martelli A; Marini V; Tamagno S; Mattioli F
    Urology; 2013 Aug; 82(2):400-4. PubMed ID: 23791221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
    Kalsi J; Harland SJ; Feneley MR
    Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy: Electromotive mitomycin in superficial bladder cancer.
    Oosterlinck W
    Nat Rev Clin Oncol; 2011 Sep; 8(11):633-4. PubMed ID: 21912417
    [No Abstract]   [Full Text] [Related]  

  • 38. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
    Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
    J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
    Tolley DA; Parmar MK; Grigor KM; Lallemand G; Benyon LL; Fellows J; Freedman LS; Grigor KM; Hall RR; Hargreave TB; Munson K; Newling DW; Richards B; Robinson MR; Rose MB; Smith PH; Williams JL; Whelan P
    J Urol; 1996 Apr; 155(4):1233-8. PubMed ID: 8632538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review.
    Carando R; Pradere B; Afferi L; Marra G; Aziz A; Roghmann F; Krajewski W; Di Bona C; Alvarez-Maestro M; Pagliarulo V; Xylinas E; Moschini M
    Prog Urol; 2020 May; 30(6):322-331. PubMed ID: 32279953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.